Innovation and Value Initiative Releases Open-Source Model for Assessing Value of EGFR+ Non-Small Cell Lung Cancer Treatment Sequences
IVI Calls for Stakeholder Community Input During Public Comment Period.
Los Angeles, CA, January 31, 2019 --(PR.com)-- The Innovation and Value Initiative (IVI) - a nonprofit organization dedicated to advancing the science and improving the practice of value assessment in healthcare - today released the initial version of its new Open-Source Value Project (OSVP) model for assessing the relative value of sequential treatments for epidermal growth factor receptor (EGFR) positive, non-squamous non-small cell lung cancer (NSCLC).
As an open-source model, the entirety of the IVI-NSCLC model package, including detailed methods documentation, R software package, source code and user interfaces, are available for access and download via IVI’s website. IVI’s open-source models are developed iteratively with feedback and suggestions from all interested healthcare stakeholders. IVI invites public input on all aspects of the first version of the IVI-NSCLC model during the public comment period, which ends April 1, 2019. All public comments will be reviewed by a Technical Expert Panel (TEP), engaged by IVI to synthesize feedback and recommend prioritized modifications for inclusion in the next model release.
“We’re pleased to release IVI’s OSVP model for non-small cell lung cancer today so value-assessment stakeholders can review, offer input and collaboratively refine not only this model, but also the underlying methods and approach to assessing relative value of therapies,” said Jennifer Bright, IVI’s Executive Director. “Collaboration is central to IVI. We know the science and practice of value assessment can only be improved when experts - from patients living with EGFR+ lung cancer to health economists to health systems - work together transparently. That’s why we believe in releasing all model information, not only for a defined comment period, but also for ongoing application, testing and refinement. We want stakeholders to constructively assess the current model and offer recommendations for its enhancement and use.”
Incorporating patients’ perspectives on value is a core goal of IVI’s OSVP models, and IVI partnered with LUNGevity Foundation to ensure input from the patient community throughout development of the new OSVP model for NSCLC. Working with LUNGevity, IVI conducted research to better understand patients’ experiences with this disease and the important considerations that drive value from their perspectives. These insights will inform the ongoing development of the IVI-NSCLC model.
“Understanding the full value of lung cancer treatments - not just average health benefits and treatment costs - is essential for patients, payers and providers,” said Andrea Ferris, President and CEO of LUNGevity. “That’s why helping IVI develop its open-source platform to transparently examine value for emerging lung cancer treatments, with the patient perspective at the forefront, is so important. Ultimately, we want to empower people with more information about which treatment course is best for them. IVI’s work to understand what’s important to patients is an important step in that direction.”
“Oncology is an area of immense clinical need, making it a prime target for assessing the value of available medical interventions,” said Mark Linthicum, IVI’s Director of Scientific Communications. “We look forward to collaborating with stakeholders to improve our models and, ultimately, to support their use by healthcare decision makers to gain valuable insights that help improve local decisions.”
About the Innovation and Value Initiative
IVI is a nonprofit committed to advancing the science and improving the practice of value assessment in healthcare through collaboration among thought leaders in academia, patient advocacy organizations, payers, life science firms and pharmaceutical manufacturers, providers, delivery systems and other organizations.
As an open-source model, the entirety of the IVI-NSCLC model package, including detailed methods documentation, R software package, source code and user interfaces, are available for access and download via IVI’s website. IVI’s open-source models are developed iteratively with feedback and suggestions from all interested healthcare stakeholders. IVI invites public input on all aspects of the first version of the IVI-NSCLC model during the public comment period, which ends April 1, 2019. All public comments will be reviewed by a Technical Expert Panel (TEP), engaged by IVI to synthesize feedback and recommend prioritized modifications for inclusion in the next model release.
“We’re pleased to release IVI’s OSVP model for non-small cell lung cancer today so value-assessment stakeholders can review, offer input and collaboratively refine not only this model, but also the underlying methods and approach to assessing relative value of therapies,” said Jennifer Bright, IVI’s Executive Director. “Collaboration is central to IVI. We know the science and practice of value assessment can only be improved when experts - from patients living with EGFR+ lung cancer to health economists to health systems - work together transparently. That’s why we believe in releasing all model information, not only for a defined comment period, but also for ongoing application, testing and refinement. We want stakeholders to constructively assess the current model and offer recommendations for its enhancement and use.”
Incorporating patients’ perspectives on value is a core goal of IVI’s OSVP models, and IVI partnered with LUNGevity Foundation to ensure input from the patient community throughout development of the new OSVP model for NSCLC. Working with LUNGevity, IVI conducted research to better understand patients’ experiences with this disease and the important considerations that drive value from their perspectives. These insights will inform the ongoing development of the IVI-NSCLC model.
“Understanding the full value of lung cancer treatments - not just average health benefits and treatment costs - is essential for patients, payers and providers,” said Andrea Ferris, President and CEO of LUNGevity. “That’s why helping IVI develop its open-source platform to transparently examine value for emerging lung cancer treatments, with the patient perspective at the forefront, is so important. Ultimately, we want to empower people with more information about which treatment course is best for them. IVI’s work to understand what’s important to patients is an important step in that direction.”
“Oncology is an area of immense clinical need, making it a prime target for assessing the value of available medical interventions,” said Mark Linthicum, IVI’s Director of Scientific Communications. “We look forward to collaborating with stakeholders to improve our models and, ultimately, to support their use by healthcare decision makers to gain valuable insights that help improve local decisions.”
About the Innovation and Value Initiative
IVI is a nonprofit committed to advancing the science and improving the practice of value assessment in healthcare through collaboration among thought leaders in academia, patient advocacy organizations, payers, life science firms and pharmaceutical manufacturers, providers, delivery systems and other organizations.
Contact
Innovation and Value Initiative
Eric Hoffman
703-548-0019
http://www.thevalueinitiative.org/
Eric Hoffman
703-548-0019
http://www.thevalueinitiative.org/
Contact
Categories